<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016302</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01857</org_study_id>
    <secondary_id>COG-AALL00P2</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <secondary_id>CDR0000068620</secondary_id>
    <nct_id>NCT00016302</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop&#xD;
      growing or die. Combining more than one drug may kill more cancer cells. This phase II trial&#xD;
      is studying several different combination chemotherapy regimens to see how well they work in&#xD;
      treating patients with newly diagnosed acute lymphoblastic leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility of the addition of nelarabine to modified multiagent&#xD;
      Berlin-Frankfurt-Muenster-86 chemotherapy in patients with newly diagnosed T-cell acute&#xD;
      lymphoblastic leukemia.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the pharmacokinetics and intracellular pharmacology of nelarabine in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, multicenter study.&#xD;
&#xD;
      Prednisone Response Pre-Induction: All patients receive oral prednisone three times daily on&#xD;
      days -7 to -1 and methotrexate intrathecally (IT) on day -7* of week 0. Good prednisone&#xD;
      responders proceed to induction on regimen A. Poor prednisone responders proceed to induction&#xD;
      on regimen C.&#xD;
&#xD;
      NOTE: *Patients who have received cytarabine IT within the week prior to study entry receive&#xD;
      methotrexate IT on day -6.&#xD;
&#xD;
      Regimen A (good prednisone responders) (closed as of 2/27/03):&#xD;
&#xD;
      Induction (weeks 1-5): Patients receive vincristine IV on days 1, 8, and 15; oral prednisone&#xD;
      three times daily on days 1-14; daunorubicin IV over 15 minutes on days 1, 8, 15, and 22;&#xD;
      asparaginase intramuscularly (IM) on days 12, 15, 18, 22, 24, 27, 30, and 33; and&#xD;
      methotrexate IT on day 1.&#xD;
&#xD;
      If bone marrow is M1, week 6 of induction therapy begins on day 36 or when peripheral blood&#xD;
      counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately.&#xD;
      If bone marrow is M3, treatment discontinues. Those patients with minimal residual disease&#xD;
      (MRD) on day 36 proceed to regimen B.&#xD;
&#xD;
      Induction (weeks 6-9): Patients receive cyclophosphamide IV over 1 hour on days 36 and 63;&#xD;
      cytarabine IV over 72 hours on days 38-40, 45-47, 52-54, and 59-61; oral mercaptopurine daily&#xD;
      on days 36-63; and methotrexate IT on days 45 and 59.&#xD;
&#xD;
      Consolidation (weeks 10-19): Patients receive oral mercaptopurine on days 64-119;&#xD;
      methotrexate IV over 24 hours and leucovorin calcium IV, or orally as tolerated, on days 71,&#xD;
      85, 99, and 113; and methotrexate IT on days 71, 85, 99, and 113. (Patients begin&#xD;
      methotrexate once blood counts recover and only if bone marrow is M1).&#xD;
&#xD;
      Reinduction (weeks 20-29): Patients receive oral dexamethasone three times daily on days&#xD;
      134-154; vincristine IV on days 141 and 148; doxorubicin IV over 15 minutes on days 134, 141,&#xD;
      148, and 155; and asparaginase IM on days 141, 144, 148, 151, 154, and 157. Beginning on day&#xD;
      169 or when blood counts recover, patients receive cyclophosphamide IV on day 169, cytarabine&#xD;
      IV over 72 hours on days 171-173 and 178-180; oral thioguanine daily on days 169-182; and&#xD;
      methotrexate IT on days 171 and 178. Patients also receive cranial irradiation for up to 10&#xD;
      days beginning on day 189.&#xD;
&#xD;
      Maintenance (weeks 30-101): Patients receive vincristine IV once; oral prednisone three times&#xD;
      daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats&#xD;
      every 8 weeks for 9 courses.&#xD;
&#xD;
      Regimen B (patients with MRD on day 36 of regimen A) (closed as of 2/27/03):&#xD;
&#xD;
      Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.&#xD;
&#xD;
      Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.&#xD;
&#xD;
      Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and&#xD;
      nelarabine IV on days 162-166.&#xD;
&#xD;
      Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and&#xD;
      36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8&#xD;
      weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral&#xD;
      prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate&#xD;
      weekly. Treatment repeats every 8 weeks for 5 courses.&#xD;
&#xD;
      Regimen C (poor prednisone responders from stage 1 of study and all patients entered during&#xD;
      stage 2 of study) (closed as of 2/27/03):&#xD;
&#xD;
      Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A&#xD;
      and nelarabine IV over 1 hour on days 29-33.&#xD;
&#xD;
      If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral&#xD;
      blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy&#xD;
      immediately. If bone marrow is M3, treatment discontinues.&#xD;
&#xD;
      Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.&#xD;
&#xD;
      Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.&#xD;
&#xD;
      Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.&#xD;
&#xD;
      Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B.&#xD;
&#xD;
      Regimen D (effective 5/2004):&#xD;
&#xD;
      Induction (weeks 1-5): Patients receive vincristine IV on days 1, 8, and 15; oral prednisone&#xD;
      3 times a day on days 1-14; daunorubicin IV over 15 minutes on days 1, 8, 15, and 22;&#xD;
      nelarabine IV over 1 hour on days 29-33; asparaginase IM on days 12, 15, 18, 22, 24, 27, 30,&#xD;
      and 33; and methotrexate IT on day 1.&#xD;
&#xD;
      If bone marrow is M1, week 6 of induction therapy begins on day 36 or when peripheral blood&#xD;
      counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately.&#xD;
      If bone marrow is M3, treatment discontinues.&#xD;
&#xD;
      Induction (weeks 6-9): Patients receive cyclophosphamide IV over 1 hour on days 36 and 50;&#xD;
      cytarabine IV or SC on days 36-39, 43-46, 50-53, and 57-60; oral mercaptopurine once daily on&#xD;
      days 36-63; and methotrexate IT on days 43 and 57.&#xD;
&#xD;
      Patients who are poor responders to prednisone in induction therapy proceed to regimen F.&#xD;
      Patients who are good responders to prednisone but have MRD after induction therapy proceed&#xD;
      to regimen E. Patients who are good responders to prednisone and have no MRD after induction&#xD;
      therapy continue therapy on regimen D.&#xD;
&#xD;
      Consolidation (weeks 10-19): Patients must have M1 marrow to proceed. Patients receive oral&#xD;
      mercaptopurine on days 70-126; methotrexate IV over 24 hours on days 77, 84, 91, and 98;&#xD;
      leucovorin calcium IV or orally every 6 hours on days 78-79, 85-86, 92-93, and 99-100; and&#xD;
      methotrexate IT on days 77, 84, 91, and 98.&#xD;
&#xD;
      Reinduction (weeks 20-29): Patients &lt; 13 years old receive dexamethasone 3 times daily on&#xD;
      days 140-161. Patients â‰¥ 13 years old receive oral dexamethasone on days 140-146 and 155-161;&#xD;
      nelarabine IV on days 169-173; vincristine IV over 15 minutes on days 140, 147, and 153;&#xD;
      pegaspargase IM on day 143; cyclophosphamide IV on day 176; cytarabine IV or SC on days&#xD;
      176-179 and 183-186; oral thioguanine on days 176-189; and methotrexate IT on days 176 and&#xD;
      183. Patients with CNS disease undergo craniocervical radiotherapy beginning on day 196 and&#xD;
      continuing for 7-10 days.&#xD;
&#xD;
      Maintenance (weeks 30-61): Patients receive oral mercaptopurine on days 1-28 and 36-56; oral&#xD;
      methotrexate on days 1, 8, 15, 22, 36, 43, and 50; and nelarabine IV on days 29-33. Treatment&#xD;
      repeats every 8 weeks for 4 courses.&#xD;
&#xD;
      Maintenance (weeks 62-101): Patients receive vincristine IV on day 1; oral dexamethasone&#xD;
      twice daily on days 1-5; oral mercaptopurine on days 1-56; and oral methotrexate on days 1,&#xD;
      8, 15, 22, 29, 36, 43, and 50. Treatment repeats every 8 weeks for 5 courses.&#xD;
&#xD;
      Regimen E (good responders to induction prednisone but with MRD) (effective 5/2004): Patients&#xD;
      receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D,&#xD;
      but nelarabine is administered at a higher dose.&#xD;
&#xD;
      Regimen F (poor responders to induction prednisone) (effective 5/2004): Patients receive&#xD;
      nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy,&#xD;
      reinduction therapy, and maintenance therapy as in regimen E.&#xD;
&#xD;
      Patients are followed monthly for 1 year, every 2 months for 1 year, every 4 months for 1&#xD;
      year, every 6 months for 1 year, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (30 for regimens A, B, and C; 70 for regimens D,&#xD;
      E, and F) will be accrued for this study within 9-29 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 3+ unusual CNS toxicities assessed using NCI CTCAE v. 3.0</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>T-cell Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.&#xD;
Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.&#xD;
Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.&#xD;
Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.&#xD;
If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.&#xD;
Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.&#xD;
Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.&#xD;
Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.&#xD;
Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>DeCortin</other_name>
    <other_name>Deltra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>daunomycin hydrochloride</other_name>
    <other_name>daunorubicin</other_name>
    <other_name>RP-13057</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>ASNase</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Crasnitin</other_name>
    <other_name>Elspar</other_name>
    <other_name>L-ASP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IT and orally</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>6-mercaptopurine</other_name>
    <other_name>6-MP</other_name>
    <other_name>Leukerin</other_name>
    <other_name>MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>6-TG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo cranial irradiation</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>506U78</other_name>
    <other_name>Arranon</other_name>
    <other_name>GW506U78</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>L-asparaginase with polyethylene glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-ASP</other_name>
    <other_name>PEG-L-asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo craniocervical radiotherapy</description>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_label>Regimen E</arm_group_label>
    <arm_group_label>Regimen F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed T-cell acute lymphoblastic leukemia with greater than 25%bone marrow&#xD;
             blasts (M3)&#xD;
&#xD;
               -  High-risk disease, defined as meeting at least 1 of the following criteria:&#xD;
&#xD;
                    -  WBC at least 50,000/mm^3&#xD;
&#xD;
                    -  Age 10 years or over&#xD;
&#xD;
          -  Patients with WBC at least 25,000/mm^3 AND at least 50% peripheral blood blasts are&#xD;
             eligible provided bone marrow aspiration was contraindicated (e.g., patient was not&#xD;
             eligible for anesthesia or sedation due to respiratory distress secondary to anterior&#xD;
             mediastinal mass)&#xD;
&#xD;
          -  Concurrent registration to POG 9900 within the past 8 days required&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (over 10 years of age)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (10 years of age and under)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGPT less than 5 times normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate at least 60 mL/min&#xD;
&#xD;
          -  No pre-existing neuropathy of grade 2 or worse unless due to leukemic infiltration&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
          -  No more than 72 hours since prior intrathecal cytarabine&#xD;
&#xD;
          -  No other prior chemotherapy&#xD;
&#xD;
          -  Prior steroids allowed&#xD;
&#xD;
          -  No chronic steroid treatment for another disease&#xD;
&#xD;
          -  Prior emergency radiotherapy to mediastinum for severe respiratory distress allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Dunsmore</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

